- Record: found
- Abstract: not found
- Article: not found
Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients With Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (Pl02.004)
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.